Get the Stockscreener App
1.85
8.19%
0.14
Serina Therapeutics Inc stock is traded at $1.85, with a volume of 25,491.
It is up +8.19% in the last 24 hours and down -21.28% over the past month.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
See More
Previous Close:
$1.71
Open:
$1.71
24h Volume:
25,491
Relative Volume:
0.64
Market Cap:
$46.99M
Revenue:
$130.00K
Net Income/Loss:
$-21.29M
P/E Ratio:
-0.9358
EPS:
-1.977
Net Cash Flow:
$-18.29M
1W Performance:
-7.96%
1M Performance:
-21.28%
6M Performance:
-8.87%
1Y Performance:
-64.08%
1-Day Range:
$1.71
$1.94
1-Week Range:
$1.71
$2.05
52-Week Range:
$1.22
$5.29
Serina Therapeutics Inc Stock (SER) Company Profile
Name
Serina Therapeutics Inc
Sector
Industry
Phone
(256) 327-9630
Address
601 GENOME WAY, HUNTSVILLE
Compare SER vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SER
Serina Therapeutics Inc
|
1.85 | 46.99M | 130.00K | -21.29M | -18.29M | -1.977 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Serina Therapeutics Inc Stock (SER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-26 | Initiated | BTIG Research | Buy |
| Jul-14-25 | Initiated | H.C. Wainwright | Buy |
Serina Therapeutics Inc Stock (SER) Latest News
Serina Therapeutics Streamlines Capital Structure After Preferred Elimination - The Globe and Mail
Serina Therapeutics, Inc. (SER) stock price, news, quote and history - Yahoo Finance UK
Serina Therapeutics CEO Steven Ledger to Discuss SER-252 Clinical Progress at Tribe Public Webinar on Advanced Parkinson’s Disease - Quiver Quantitative
Serina Therapeutics at H.C. Wainwright conference: Parkinson’s push advances By Investing.com - Investing.com South Africa
Serina Therapeutics at H.C. Wainwright conference: Parkinson’s push advances By Investing.com - Investing.com Canada
Serina Therapeutics at H.C. Wainwright conference: Parkinson’s push advances - Investing.com India
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Serina Therapeutics will present its neurological disease work Sept. 14. - Stock Titan
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewswire
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Serina Therapeutics Announces Independent Committee Recommends Advance of SER-252 Parkinson’s Study to Cohort 2 | SER Stock News - Quiver Quantitative
Some Parkinson’s patients showed sustained motor improvement in Serina’s study - Stock Titan
SER: Serina Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - stocktwits.com
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2 - Yahoo Finance
Serina Therapeutics Reports Cohort 1 Observations from - GlobeNewswire
Serina Therapeutics (SER) Dips 2.40% to $2.44, Testing Key Support at $2.32Block Trade Flow - vinanet.vn
Serina Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Serina Therapeutics Establishes Flexible Equity Financing Agreement - The Globe and Mail
Serina Therapeutics Inc (SER-A) Stock Price and News - The Globe and Mail
Serina Therapeutics Secures $25 Million Equity Financing Facility with Roth Principal - Minichart
Serina Therapeutics Sets Up $25 Million Equity Purchase Facility With Roth Principal Investments - TradingView
IPO Databook: Serina Therapeutics (SER US)Aug 2026 - Smartkarma
Serina TherapeuticsOffers Up To 12,500,000 Shares Of Common Stock By Roth Principal InvestmentsSEC Filing - TradingView
BTIG Maintains Serina Therapeutics(SER.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Serina Therapeutics, Inc. announced that it expects to receive $25 million in funding from Roth Principal Investments, LLC - marketscreener.com
Serina (SER) Move: Ends Lower by 1.53% at $2.58 in the Latest Reading; Next Session: the Near-Term Reference Band Stretches From $2.45 to $2.71 in the Available RecordSwing Entry Signals - vinanet.vn
Serina Therapeutics Q2 loss widens to $(0.55) as revenue drops to zero - scanx.trade
Serina Therapeutics Completes Dosing for 8 Parkinson’s Patients - Stock Titan
Serina Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - GlobeNewswire
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - Yahoo Finance
SER Q1 2026 Earnings: Wider Loss Falls Short of Estimates Despite Modest Share GainEarnings Trend Analysis - vinanet.vn
Serina Therapeutics Inc (SER) Stock News Today - TradingKey
Serina Therapeutics Inc (SER) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Serina Therapeutics (SER) Holds Steady Above $2.24 Support, Up 0.43% in Measured SessionDelta Hedging - vinanet.vn
Serina Therapeutics (SER) Advances 5.83% to $2.18, Approaching Key Resistance at $2.29McClellan Summation - dars.gov.et
SER Q1 2026 Earnings: Wider-than-Expected Loss of -$0.58 per Share Signals Rising Pipeline CostsEarnings Call Highlights - vinanet.vn
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineReturn On Equity - dars.gov.et
Serina Therapeutics Inc. (SER) Holds Steady Near $2.07 as Traders Eye Tight Trading RangeETF AUM Growth - dars.gov.et
Serina Therapeutics Inc. (SER) Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues to Invest in PipelineEarnings Surprise Score - careplusvn.com
Serina Therapeutics Inc (SER) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Serina Therapeutics Inc (SER) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
SER|Serina Therapeutics Inc|Price:2.030|Chg%:-0.040 - TradingKey
Serina Therapeutics Market Sentiment - Benzinga España
Serina Therapeutics Inc (SER) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Serina Therapeutics Inc (SER) Balance Sheet - TradingKey
Serina Therapeutics, Inc. Revenue Breakdown – AMEX:SER - TradingView
Serina Therapeutics, Inc. Revenue Breakdown – TRADEGATE:2BO - TradingView
TradingKey - TradingKey
Serina Therapeutics Inc (SER) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Serina Therapeutics Inc Stock (SER) Financials Data
Revenue
Net Income
Cash Flow
EPS
Serina Therapeutics Inc Stock (SER) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WILSON KAREN J | Director |
Jun 12 '26 |
Buy |
1.77 |
5,000 |
8,850 |
10,100 |
| WILSON KAREN J | Director |
Jun 11 '26 |
Buy |
1.75 |
5,100 |
8,900 |
5,100 |
| Venkatesan Jay | Director |
May 22 '26 |
Buy |
1.78 |
589 |
1,048 |
589 |
| WILSON KAREN J | Director |
May 22 '26 |
Buy |
1.93 |
10,000 |
19,300 |
20,000 |
| WILSON KAREN J | Director |
May 21 '26 |
Buy |
1.77 |
10,000 |
17,700 |
10,000 |
| Marshall Richard Peter | Director |
May 19 '26 |
Buy |
1.65 |
12,183 |
20,102 |
12,183 |
| Moreadith Randall | Chief Scientific Officer |
Mar 23 '26 |
Option Exercise |
0.06 |
6,500 |
390 |
6,500 |
| Moreadith Randall | Chief Scientific Officer |
Mar 23 '26 |
Sale |
2.86 |
6,500 |
18,568 |
0 |
| Moreadith Randall | Chief Scientific Officer |
Mar 19 '26 |
Sale |
2.50 |
39,000 |
97,500 |
0 |
| Moreadith Randall | Chief Scientific Officer |
Mar 19 '26 |
Option Exercise |
0.06 |
39,000 |
2,340 |
39,000 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):